Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ARTELO BIOSCIENCES, INC. incurred convertible notes of $690,154.69 at 12% per annum maturing six months after the closing of the Notes Offering.
- Instrument
- convertible notes
- Principal
- $690,154.69
- Rate
- 12% per annum
- Maturity
- six months after the closing of the Notes Offering
- Event
- incurrence
Exact text from the filing
On October 28, 2025, Artelo Biosciences, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) pursuant to which it issued and sold to certain investors (the “ Investors ”), and the Investors purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes ”) to the Investors in an aggregate principal amount of $690,154.69;
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
ARTELO BIOSCIENCES, INC. issued Aggregate principal amount of $690,154.69 of convertible notes of convertible note to certain investors for Conversion of all or a portion of the unconverted 'Voluntary Conversion' portion of unpaid principal balance and accrued interest due upon maturity of convertib.
- Security
- convertible note
- Shares
- Aggregate principal amount of $690,154.69 of convertible notes
- Purchaser
- certain investors
- Consideration
- Conversion of all or a portion of the unconverted 'Voluntary Conversion' portion of unpaid principal balance and accrued interest due upon maturity of convertib
Exact text from the filing
On October 28, 2025, Artelo Biosciences, Inc. (the " Company ") entered into a Subscription Agreement (the " Subscription Agreement ") pursuant to which it issued and sold to certain investors (the " Investors "), and the Investors purchased (by converting all or a portion of the unconverted "Voluntary Conversion" portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the " Notes ") to the Investors in an aggregate principal amount of $690,154.69; and (ii) warrants (the " Warrants ") to purchase an aggregate of 438,182 shares of the Company's common stock, par value $0.001 per share (" Common Stock "), at an exercise price of $3.40 per share (collectively, the " Offering ").
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
ARTELO BIOSCIENCES, INC. issued 438,182 shares of common stock underlying warrants of warrant to certain investors for Part of the same consideration as the notes; warrants issued in the same transaction.
- Security
- warrant
- Shares
- 438,182 shares of common stock underlying warrants
- Purchaser
- certain investors
- Consideration
- Part of the same consideration as the notes; warrants issued in the same transaction
Exact text from the filing
On October 28, 2025, Artelo Biosciences, Inc. (the " Company ") entered into a Subscription Agreement (the " Subscription Agreement ") pursuant to which it issued and sold to certain investors (the " Investors "), and the Investors purchased (by converting all or a portion of the unconverted "Voluntary Conversion" portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the " Notes ") to the Investors in an aggregate principal amount of $690,154.69; and (ii) warrants (the " Warrants ") to purchase an aggregate of 438,182 shares of the Company's common stock, par value $0.001 per share (" Common Stock "), at an exercise price of $3.40 per share (collectively, the " Offering ").
View on SEC.gov